Imuran Indications/Uses

Imuran is indicated for the treatment of patients who have received an organ transplant.
Imuran has a significant therapeutic effect in a proportion of patient suffering from chronic active hepatitis, severe rheumatoid arthritis, systemic lupus erythematosus (SLE), dermatomyositis, pemphigus vulgaris, polyarteritis nodosa, acquired hemolytic anemia, idiopathic thrombocytopenic purpura.
Imuran is used in conditions other than transplantation, when: they are refractory to corticosteroids alone, or they are controlled by corticosteroids in dosages producing or likely to produce severe side effects and the primary aim is to reduce the requirements of steroids; or corticosteroids are contra-indicated.
In pemphigus and rheumatoid arthritis, Imuran has been shown to have significant therapeutic activity when used without corticosteroids. In other conditions or where local registration authority approval has not yet been given for a particular condition, the use of Imuran must be regarded as experimental. The risk associated with therapy with Imuran should be considered against the severity of the patient's condition and the prospects of therapeutic benefit.